INTRA CELLULAR THERAPIES INC's ticker is ITCI and the CUSIP is 46116X101. A total of 241 filers reported holding INTRA CELLULAR THERAPIES INC in Q1 2022. The put-call ratio across all filers is 0.55 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $10,935,514 | -1.6% | 209,935 | +2.3% | 0.01% | 0.0% |
| Q2 2023 | $11,117,645 | 0.0% | 205,312 | 0.0% | 0.01% | 0.0% |
| Q1 2023 | $11,117,645 | +4.7% | 205,312 | +2.3% | 0.01% | -16.7% |
| Q4 2022 | $10,621,731 | -99.9% | 200,713 | +8.0% | 0.01% | +20.0% |
| Q3 2022 | $8,646,763,000 | -37.3% | 185,832 | -23.1% | 0.01% | -28.6% |
| Q2 2022 | $13,784,877,000 | -8.9% | 241,501 | -2.3% | 0.01% | +16.7% |
| Q1 2022 | $15,128,246,000 | +294.9% | 247,234 | +237.8% | 0.01% | +500.0% |
| Q4 2021 | $3,831,080,000 | +22.7% | 73,196 | -12.6% | 0.00% | 0.0% |
| Q3 2021 | $3,122,051,000 | -4.3% | 83,746 | +4.8% | 0.00% | 0.0% |
| Q2 2021 | $3,261,558,000 | +43.0% | 79,901 | +18.9% | 0.00% | 0.0% |
| Q1 2021 | $2,280,367,000 | +6.0% | 67,208 | -0.6% | 0.00% | 0.0% |
| Q4 2020 | $2,151,079,000 | +62.1% | 67,644 | +30.8% | 0.00% | 0.0% |
| Q3 2020 | $1,326,674,000 | +10.9% | 51,702 | +11.0% | 0.00% | 0.0% |
| Q2 2020 | $1,195,915,000 | +67.2% | 46,588 | +0.1% | 0.00% | 0.0% |
| Q1 2020 | $715,365,000 | -46.0% | 46,543 | +20.5% | 0.00% | 0.0% |
| Q4 2019 | $1,324,812,000 | +337.0% | 38,613 | -4.8% | 0.00% | – |
| Q3 2019 | $303,140,000 | -25.8% | 40,581 | +29.0% | 0.00% | – |
| Q2 2019 | $408,403,000 | +10.6% | 31,464 | +3.8% | 0.00% | – |
| Q1 2019 | $369,298,000 | +120.6% | 30,320 | +106.3% | 0.00% | – |
| Q4 2018 | $167,433,000 | -47.5% | 14,700 | 0.0% | 0.00% | – |
| Q3 2018 | $318,990,000 | +22.8% | 14,700 | 0.0% | 0.00% | – |
| Q2 2018 | $259,749,000 | -16.1% | 14,700 | 0.0% | 0.00% | – |
| Q1 2018 | $309,435,000 | +45.4% | 14,700 | 0.0% | 0.00% | – |
| Q4 2017 | $212,856,000 | +77021.7% | 14,700 | -18.8% | 0.00% | – |
| Q3 2016 | $276,000 | -60.7% | 18,100 | 0.0% | 0.00% | -100.0% |
| Q2 2016 | $703,000 | +39.8% | 18,100 | 0.0% | 0.00% | 0.0% |
| Q1 2016 | $503,000 | -55.5% | 18,100 | -13.9% | 0.00% | 0.0% |
| Q4 2015 | $1,131,000 | +128.0% | 21,011 | +69.4% | 0.00% | 0.0% |
| Q3 2015 | $496,000 | +80.4% | 12,400 | +44.2% | 0.00% | – |
| Q2 2015 | $275,000 | – | 8,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ally Bridge Group (NY) LLC | 175,000 | $9,115,750 | 10.70% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 317,856 | $16,547,583 | 5.57% |
| Deep Track Capital, LP | 2,600,000 | $135,434,000 | 5.23% |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1,369,849 | $71,355,434 | 3.86% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 208,730 | $10,872,746 | 3.30% |
| DCF Advisers, LLC | 107,157 | $5,581,808 | 3.04% |
| Bellevue Group AG | 3,170,250 | $165,138,323 | 2.66% |
| Vahanian & Associates Financial Planning Inc. | 15,217 | $792,654 | 2.55% |
| Iron Triangle Partners LP | 330,549 | $17,218,297 | 2.52% |
| TANG CAPITAL MANAGEMENT LLC | 300,000 | $15,627,000 | 2.20% |